- Starts: 14 April 2018
- Ends: 18 April 2018
- Website: Click to view
The Almac Discovery team are delighted to announce they will be attending this year’s AACR Annual Meeting in Chicago, Illinois.
- Tim Harrison, Vice President Discovery Chemistry
- Martin Wiles, Vice President Business Development & Licensing
- Dr Gerald Gavory, Head of Biology
Almac Discovery will be presenting the following posters:
Discovery and characterization of highly potent and selective USP7 inhibitors and benchmarking against clinical MDM2 antagonists
- Session Category: Experimental and Molecular Therapeutics Session
- Title: Novel Targets and Inhibitors
- Session Date and Time: Tuesday Apr 17, 2018 1:00 PM – 5:00 PM
- Location: McCormick Place South, Exhibit Hall A, Poster Section 39
- Poster Board Number: 14
- Permanent Abstract Number: 4869
Accessing the cancer DUBome with UbiPlex®: A bespoke drug discovery platform for deubiquitinase enzymes
- Session Category: Experimental and Molecular Therapeutics
- Session Title: New Targets 1
- Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
- Location: McCormick Place South, Exhibit Hall A, Poster Section 40
- Poster Board Number: 10
- Permanent Abstract Number: 1935
Presenter: Dr Gerald Gavory
Gerald has responsibility for the company’s drug discovery and pre-clinical development activities and was instrumental in implementing the deubiquitylating enzyme research platform at Almac Discovery. Prior to joining Almac Discovery in 2010, Gerald worked at Merck & Co as a senior scientist where he notably contributed towards the identification and development of PARP inhibitors including Niraparib (MK-4827). Gerald was a post-doctoral fellow at Cambridge University and received his PhD in Biological Sciences in 2003 from the same university in the laboratory of Prof. S. Balasubramanian.
Ubiquitin Specific Proteases (USPs) have proven to be particularly difficult to target with small molecules over the past decade, however, we at Almac Discovery are committed to change that.
For more information on Almac Discovery’s work with Ubiquitin Specific Proteases, click here.
Presentations at the Annual Meeting will cover the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations. We will feature new sessions on cancer health disparities that have been inspired by one of the important AACR presidential initiatives. We will also be reprising a popular new feature from Annual Meeting 2017, “Unsolved Mysteries,” featuring provocative questions and their in-depth discussion by speakers and members of the audience.